{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:26:25Z","timestamp":1794619585725,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"DOI":"10.1186\/s12887-024-05100-7","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T05:01:51Z","timestamp":1727499711000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Serum salicylic acid levels in children with Kawasaki disease"],"prefix":"10.1186","volume":"24","author":[{"given":"Hitoshi","family":"Honma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Sada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Somiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taichiro","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihisa","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,28]]},"reference":[{"key":"5100_CR1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/ped.12317","volume":"56","author":"Research Committee of the Japanese Society of Pediatric Cardiology, Cardiac Surgery Committee for Development of Guidelines for Medical Treatment of Acute Kawasaki Disease","year":"2014","unstructured":"Research Committee of the Japanese Society of Pediatric Cardiology, Cardiac Surgery Committee for Development of Guidelines for Medical Treatment of Acute Kawasaki Disease. Guidelines for medical treatment of acute Kawasaki disease: report of the Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac surgery (2012 revised version). Pediatr Int. 2014;56:135\u201358.","journal-title":"Pediatr Int"},{"key":"5100_CR2","first-page":"41","volume":"5","author":"Research Committee of the Japanese Society of Pediatric Cardiology; Cardiac Surgery Committee for Development of Guidelines for Medical Treatment of Acute Kawasaki Disease","year":"2021","unstructured":"Research Committee of the Japanese Society of Pediatric Cardiology; Cardiac Surgery Committee for Development of Guidelines for Medical Treatment of Acute Kawasaki Disease. Guidelines for medical treatment of acute Kawasaki disease (2020 revised version). J Pediatr Cardiol Card Surg. 2021;5:41\u201373.","journal-title":"J Pediatr Cardiol Card Surg"},{"key":"5100_CR3","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S0140-6736(84)91504-6","volume":"2","author":"K Furusho","year":"1984","unstructured":"Furusho K, Kamiya T, Nakano H, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet. 1984;2:1055\u20138.","journal-title":"Lancet"},{"key":"5100_CR4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJM198608073150601","volume":"315","author":"JW Newburger","year":"1986","unstructured":"Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315:341\u20137.","journal-title":"N Engl J Med"},{"key":"5100_CR5","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1056\/NEJM199106063242305","volume":"324","author":"JW Newburger","year":"1991","unstructured":"Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324:1633\u20139.","journal-title":"N Engl J Med"},{"key":"5100_CR6","doi-asserted-by":"publisher","first-page":"e927","DOI":"10.1161\/CIR.0000000000000484","volume":"135","author":"BW McCrindle","year":"2017","unstructured":"McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135:e927\u201399.","journal-title":"Circulation"},{"key":"5100_CR7","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S0022-3476(84)80097-9","volume":"105","author":"G Koren","year":"1984","unstructured":"Koren G, MacLeod SM. Difficulty in achieving therapeutic serum concentrations of salicylate in Kawasaki disease. J Pediatr. 1984;105:991\u20135.","journal-title":"J Pediatr"},{"key":"5100_CR8","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/BF02072625","volume":"150","author":"T Akagi","year":"1991","unstructured":"Akagi T, Kato H, Inoue O, Sato N. Salicylate treatment in Kawasaki disease: high dose or low dose? Eur J Pediatr. 1991;150:642\u20136.","journal-title":"Eur J Pediatr"},{"key":"5100_CR9","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S0022-3476(88)80194-X","volume":"112","author":"G Koren","year":"1988","unstructured":"Koren G, Schaffer F, Silverman E, et al. Determinants of low serum concentrations of salicylates in patients with Kawasaki disease. J Pediatr. 1988;112:663\u20137.","journal-title":"J Pediatr"},{"key":"5100_CR10","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/S0022-3476(05)82168-7","volume":"118","author":"G Koren","year":"1991","unstructured":"Koren G, Silverman E, Sundel R, et al. Decreased protein binding of salicylates in Kawasaki disease. J Pediatr. 1991;118:456\u20139.","journal-title":"J Pediatr"},{"key":"5100_CR11","doi-asserted-by":"publisher","first-page":"e689","DOI":"10.1542\/peds.2004-1037","volume":"114","author":"KS Hsieh","year":"2004","unstructured":"Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM. Treatment of acute Kawasaki disease: aspirin\u2019s role in the febrile stage revisited. Pediatrics. 2004;114:e689\u201393.","journal-title":"Pediatrics"},{"key":"5100_CR12","doi-asserted-by":"publisher","first-page":"e20170098","DOI":"10.1542\/peds.2017-0098","volume":"139","author":"F Dallaire","year":"2017","unstructured":"Dallaire F, Fortier-Morissette Z, Blais S, et al. Aspirin dose and prevention of coronary abnormalities in Kawasaki disease. Pediatrics. 2017;139:e20170098.","journal-title":"Pediatrics"},{"key":"5100_CR13","doi-asserted-by":"publisher","first-page":"e0144603","DOI":"10.1371\/journal.pone.0144603","volume":"10","author":"HC Kuo","year":"2015","unstructured":"Kuo HC, Lo MH, Hsieh KS, Guo MM, Huang YH. High-dose aspirin is associated with anemia and does not confer benefit to disease outcomes in Kawasaki disease. PLoS ONE. 2015;10:e0144603.","journal-title":"PLoS ONE"},{"key":"5100_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jpeds.2016.12.019","volume":"184","author":"GB Kim","year":"2017","unstructured":"Kim GB, Yu JJ, Yoon KL, et al. Medium- or higher-dose acetylsalicylic acid for acute Kawasaki disease and patient outcomes. J Pediatr. 2017;184:125\u2013e91.","journal-title":"J Pediatr"},{"key":"5100_CR15","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/ped.14326","volume":"62","author":"T Kobayashi","year":"2020","unstructured":"Kobayashi T, Ayusawa M, Suzuki H, et al. Revision of diagnostic guidelines for Kawasaki disease (6th revised edition). Pediatr Int. 2020;62:1135\u20138.","journal-title":"Pediatr Int"},{"key":"5100_CR16","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1161\/CIRCULATIONAHA.105.592865","volume":"113","author":"T Kobayashi","year":"2006","unstructured":"Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006;113:2606\u201312.","journal-title":"Circulation"},{"key":"5100_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jpeds.2006.03.050","volume":"149","author":"K Egami","year":"2006","unstructured":"Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr. 2006;149:237\u201340.","journal-title":"J Pediatr"},{"key":"5100_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00431-006-0223-z","volume":"166","author":"T Sano","year":"2007","unstructured":"Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr. 2007;166:131\u20137.","journal-title":"Eur J Pediatr"},{"key":"5100_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1046\/j.1442-200x.2000.01225.x","volume":"42","author":"T Kawamura","year":"2000","unstructured":"Kawamura T, Wago M, Kawaguchi H, Tahara M, Yuge M. Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease. Pediatr Int. 2000;42:241\u20138.","journal-title":"Pediatr Int"},{"key":"5100_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"5100_CR21","unstructured":"Arif H, Aggarwal S. Salicylic Acid (Aspirin). In: StatPearls. 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK519032\/. Accessed 29 Jul 2024."},{"key":"5100_CR22","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2165\/00003088-198510020-00004","volume":"10","author":"CJ Needs","year":"1985","unstructured":"Needs CJ, Brooks PM. Clinical pharmacokinetics of the salicylates. Clin Pharmacokinet. 1985;10:164\u201377.","journal-title":"Clin Pharmacokinet"},{"key":"5100_CR23","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1001\/jama.1965.03090190023006","volume":"194","author":"JR Klinenberg","year":"1965","unstructured":"Klinenberg JR, Miller F. Effect of corticosteroids on blood salicylate concentration. JAMA. 1965;194:601\u20134.","journal-title":"JAMA"},{"key":"5100_CR24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/00007691-198706000-00009","volume":"9","author":"G Koren","year":"1987","unstructured":"Koren G, Roifman C, Gelfand E, Lavi S, Suria D, Stein L. Corticosteroids-salicylate interaction in a case of juvenile rheumatoid arthritis. Ther Drug Monit. 1987;9:177\u20139.","journal-title":"Ther Drug Monit"},{"key":"5100_CR25","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1542\/peds.96.6.1057","volume":"96","author":"K Durongpisitkul","year":"1995","unstructured":"Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics. 1995;96:1057\u201361.","journal-title":"Pediatrics"},{"key":"5100_CR26","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S0022-3476(97)70038-6","volume":"131","author":"M Terai","year":"1997","unstructured":"Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr. 1997;131:888\u201393.","journal-title":"J Pediatr"},{"key":"5100_CR27","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/rheumatology\/keaa050","volume":"59","author":"X Jia","year":"2020","unstructured":"Jia X, Du X, Bie S, Li X, Bao Y, Jiang M. What dose of aspirin should be used in the initial treatment of Kawasaki disease? A meta-analysis. Rheumatology (Oxford). 2020;59:1826\u201333.","journal-title":"Rheumatology (Oxford)"},{"key":"5100_CR28","doi-asserted-by":"publisher","first-page":"e0217274","DOI":"10.1371\/journal.pone.0217274","volume":"14","author":"X Zheng","year":"2019","unstructured":"Zheng X, Yue P, Liu L, et al. Efficacy between low and high dose aspirin for the initial treatment of Kawasaki disease: current evidence based on a meta-analysis. PLoS ONE. 2019;14:e0217274.","journal-title":"PLoS ONE"},{"key":"5100_CR29","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1136\/archdischild-2019-318245","volume":"106","author":"MH Chiang","year":"2021","unstructured":"Chiang MH, Liu HE, Wang JL. Low-dose or no aspirin administration in acute-phase Kawasaki disease: a meta-analysis and systematic review. Arch Dis Child. 2021;106:662\u20138.","journal-title":"Arch Dis Child"},{"key":"5100_CR30","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12969-020-00432-x","volume":"18","author":"J Wang","year":"2020","unstructured":"Wang J, Chen H, Shi H, et al. Effect of different doses of aspirin on the prognosis of Kawasaki disease. Pediatr Rheumatol Online J. 2020;18:48.","journal-title":"Pediatr Rheumatol Online J"},{"key":"5100_CR31","first-page":"209","volume":"35","author":"G Amarilyo","year":"2017","unstructured":"Amarilyo G, Koren Y, Brik Simon D, et al. High-dose aspirin for Kawasaki disease: outdated myth or effective aid? Clin Exp Rheumatol. 2017;35:209\u201312.","journal-title":"Clin Exp Rheumatol"},{"key":"5100_CR32","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/jpc.13816","volume":"54","author":"X Huang","year":"2018","unstructured":"Huang X, Huang P, Zhang L, et al. Is aspirin necessary in the acute phase of Kawasaki disease? J Paediatr Child Health. 2018;54:661\u20134.","journal-title":"J Paediatr Child Health"},{"key":"5100_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2024.03.010","volume":"273","author":"Y Wu","year":"2024","unstructured":"Wu Y, Hu L, Xie X, et al. Different dose aspirin plus immunoglobulin (DAPI) for prevention of coronary artery abnormalities in Kawasaki disease: study protocol for a multi-center, prospective, randomized, open-label, blinded end-point, non-inferiority trial. Am Heart J. 2024;273:1\u20139.","journal-title":"Am Heart J"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-024-05100-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-024-05100-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-024-05100-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T05:02:48Z","timestamp":1727499768000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-024-05100-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,28]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5100"],"URL":"https:\/\/doi.org\/10.1186\/s12887-024-05100-7","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,28]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Aichi Medical University School of Medicine (approval no. 2024-098). This study adhered to the tenets of the Declaration of Helsinki. Informed consent was obtained from all participants and\/or their caregivers.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"KD, Kawasaki disease.CALs, Coronary artery lesions.IVIG, Intravenous immunoglobulin.ASA, Acetylsalicylic acid.SA, Salicylic acid.AST, Aspartate aminotransferase.ALT, Alanine aminotransferase.WBC, White blood cell.PLT, Platelet.T-Bil, Total bilirubin.Alb, Albumin.Na, Sodium.CRP, C-reactive protein.BNP, Brain natriuretic peptide.cKD, Complete Kawasaki disease.iKD, Incomplete Kawasaki disease.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Abbreviations"}}],"article-number":"613"}}